Drug Development Solutions
Drug Development Solutions is recorded as a service provider in 53 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 53 trials · Latest update first
An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
Operational learnings available8 trial-level findings · Read insights
- Recruitment began on 1 March 2022, and 98 participants were randomized at 57 sites in 19 countries.
- A May 2022 amendment changed the primary endpoint from complete remission on minimal OCS to CRoff at week 36 and added CRmin and IGA-BP-off-OCS secondary endpoints.
- Infection-related eligibility criteria were tightened across amendments, including exclusion of active or chronic infections and later clinically significant active infection unresolved before baseline.
- A March 2023 amendment added exclusions for latent infection, severe renal impairment, specified safety or procedure-affecting conditions, concurrent interventional-study enrollment, inadequately treated HIV, and recent live or live-attenuated vaccination.
- Sponsor confirmation of participant eligibility was removed in the March 2023 amendment.
- The March 2023 amendment required at least 30 minutes of on-site safety monitoring after investigational-product administration, and this requirement was removed in February 2024.
- The Day 10 PK sampling requirement in Part A was clarified to require samples from at least 28 participants rather than all participants.
- All adverse events in the MedDRA Infections and Infestations system organ class were designated adverse events of special interest in the May 2022 amendment.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
Sponsor Corcept Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy
Sponsor Argenx
- Start (EU)
- Not reported
- Latest update
- Estimated end
Master Protocol Full Title: A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 1 Full Title: An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod.
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species
Sponsor F2G Limited
- Start (EU)
- Latest update
- Estimated end
A 52-week, randomized, double-blind, placebo-controlled, parallel-group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis.
Sponsor Chiesi Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The study was stopped early in China because the lack of effect on moderate/severe flare-ups observed in other countries was also considered applicable there.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Parallel-Group, Observer-Blind, Randomised, Placebo-Controlled, Pivotal Trial Investigating the Safety and Immunogenicity of Group B Streptococcus Vaccine (GBS-NN/NN2) in Pregnant Women and Infants Born to Pregnant Women Vaccinated During Pregnancy
Sponsor Minervax ApS
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and safety of Debio 4126, a 12-week octreotide formulation, in patients with acromegaly previously treated with somatostatin analogs.
Sponsor Debiopharm International S.A.
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Across 16 sites in six countries, 13 participants were enrolled: France enrolled 7, Finland and Germany enrolled 2 each, Australia and Japan enrolled 1 each, and five United States sites enrolled none.
- The study terminated during Phase 1 Arm A; Phase 1 Arm B dose escalation and Phase 2 dose expansion were not initiated.
- Two participants (15.4%) were excluded from the DLT-evaluable set because they permanently discontinued treatment before completing the DLT-assessment period for reasons other than study treatment-related toxicity.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Not reported
- Latest update
- Estimated end
A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)
Sponsor Anthos Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1
Sponsor Spur Therapeutics Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
An open-label extension study to evaluate rozanolixizumab in pediatric study participants with generalized myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
Sponsor Corcept Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Drug Development Solutions?
The 2026-10-09 snapshot links Drug Development Solutions to 53 distinct CTIS trials. Recorded services include Laboratory services, Analysis of Pharmacokinetics and Anti-Drug Antibodies (ADA), ADA, NAB analysis, Analysis of PK samples, among 22 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Drug Development Solutions?
The most frequently recorded therapeutic areas are Immunology, Neurology, Endocrinology, Haematological Malignancies. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Drug Development Solutions conducted?
The linked trials record locations in 26 countries, including Italy, Germany, Poland, Spain, France. These are trial locations, not confirmed office locations or countries where Drug Development Solutions delivered services.
What can this page tell me about Drug Development Solutions's trial experience?
Browse 53 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Drug Development Solutions. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Drug Development Solutions Limited